See more : Hallador Energy Company (HNRG) Income Statement Analysis – Financial Results
Complete financial analysis of Avidity Biosciences, Inc. (RNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avidity Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nagambie Resources Limited (NAG.AX) Income Statement Analysis – Financial Results
- OOOOO Entertainment Commerce Limited (OOOO.V) Income Statement Analysis – Financial Results
- ClearStream Energy Services Inc. (CSM.TO) Income Statement Analysis – Financial Results
- Prime Oil Chemical Service Corporation (2904.TW) Income Statement Analysis – Financial Results
- TransAlta Corporation (TAC) Income Statement Analysis – Financial Results
Avidity Biosciences, Inc. (RNA)
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9.56M | 9.22M | 9.33M | 6.79M | 2.32M | 379.00K |
| Cost of Revenue | 2.10M | 1.39M | 639.00K | 37.60M | 14.54M | 8.44M |
| Gross Profit | 7.46M | 7.84M | 8.69M | -30.82M | -12.22M | -8.06M |
| Gross Profit Ratio | 78.02% | 84.96% | 93.15% | -454.03% | -526.95% | -2,125.86% |
| Research & Development | 190.97M | 150.40M | 101.18M | 37.60M | 14.54M | 8.44M |
| General & Administrative | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Other Expenses | 0.00 | 4.92M | 42.00K | -78.00K | 0.00 | 0.00 |
| Operating Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Cost & Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Interest Income | 23.97M | 4.98M | 104.00K | 206.00K | 7.39M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 209.00K | 7.39M | 718.00K |
| Depreciation & Amortization | 2.10M | 1.39M | 639.00K | 373.00K | 597.00K | 383.00K |
| EBITDA | -233.50M | -177.53M | -117.41M | -43.77M | -16.75M | -10.12M |
| EBITDA Ratio | -2,442.44% | -1,939.65% | -1,265.83% | -652.38% | -732.38% | -2,668.87% |
| Operating Income | -235.60M | -178.91M | -118.05M | -44.28M | -17.33M | -10.50M |
| Operating Income Ratio | -2,464.41% | -1,939.65% | -1,265.83% | -652.38% | -747.39% | -2,769.92% |
| Total Other Income/Expenses | 23.38M | 4.92M | 42.00K | -78.00K | -7.40M | -718.00K |
| Income Before Tax | -212.22M | -174.00M | -118.01M | -44.36M | -24.73M | -11.22M |
| Income Before Tax Ratio | -2,219.87% | -1,886.33% | -1,265.38% | -653.53% | -1,066.58% | -2,959.37% |
| Income Tax Expense | 0.00 | -4.92M | -639.00K | -373.00K | 7.39M | 718.00K |
| Net Income | -212.22M | -169.08M | -117.37M | -43.98M | -32.12M | -11.93M |
| Net Income Ratio | -2,219.87% | -1,833.01% | -1,258.52% | -648.03% | -1,385.12% | -3,148.81% |
| EPS | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| EPS Diluted | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| Weighted Avg Shares Out | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
| Weighted Avg Shares Out (Dil) | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
Avidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology
Avidity Biosciences' stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-oligonucleotide technology candidate in treating myotonic dystrophy type 1. The next price-moving catalyst is the updated Phase 1/2 MARINA trial...
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Business wins are shining the spotlight on these two companies.
RNA Breakthrough Sends Biotech Stock Surging
Avidity Biosciences Inc (NASDAQ:RNA) is soaring this morning, after the biotech company shared positive data from a trial demonstrating the first-ever successful targeted delivery of RNA into muscle.
Avidity's stock rallies 39% on new RNA data
Shares of Avidity Biosciences Inc. RNA, -4.52% soared 39% in premarket trading on Wednesday after the company said its experimental RNA therapy, when injected into the muscle, has potential as a treatment for myotonic dystrophy type 1, a sometimes fatal...
Down 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)
The heavy selling pressure might have exhausted for Avidity Biosciences, Inc. (RNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the...
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. – RNA
NEW YORK, Oct. 10, 2022 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. (“Avidity” or the “Company”) (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study
Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.
Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study
The FDA placed a myotonic dystrophy study from Avidity Biosciences on partial hold Tuesday, leading RNA stock to collapse. The post Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study appeared first on Investor's Business Daily.
Avidity shares fall 23% after announcing partial clinical hold for myotonic dystrophy trial
Shares of Avidity Biosciences Inc. RNA, +1.13% tumbled 23.7% in premarket trading on Tuesday after the company said the Food and Drug Administration placed a partial clinical hold on new enrollment in a Phase 1/2 clinical trial trial evaluating a...
Source: https://incomestatements.info
Category: Stock Reports